INNER CITY ASTHMA CONSORTIUM

内城哮喘协会

• 批准号: 7952351
• 负责人: William W. Busse
• 金额: $ 5628.99万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952351
• 关键词: INNER; CITY; ASTHMA; CONSORTIUM

The objectives of the Inner City Asthma Consortium are to implement a long range scientific plan to reduce asthma severity and prevent asthma among inner city children and to identify the mechanisms involved in the immunopathogenesis of asthma in these populations. The specific objectives are to: 1) conduct clinical trials to evaluate the safety and efficacy of promising immune based therapies in reducing asthma severity and preventing disease onset in minority children residing in inner cities in the United States; 2) conduct research to delineate the underlying mechanisms of such therapies as an integral part of the clinical trials undertaken by the Consortium; 3) conduct clinical studies on the immunopathogenesis of asthma onset, progression and severity ; and 4) develop and validate surrogate / biomarkers to measure disease stage, progression and therapeutic effect.

内城哮喘联盟的目标是实施一项长期的科学计划，以降低内城儿童的哮喘严重程度和预防哮喘，并确定这些人群中哮喘的免疫发病机制。具体目标是：1)开展临床试验，评估有希望的免疫疗法在降低美国城市内少数民族儿童哮喘严重程度和预防疾病发作方面的安全性和有效性；2)开展研究，以描述这些疗法的潜在机制，作为该联盟开展的临床试验的组成部分；3)开展哮喘发病、进展及严重程度的免疫发病机制的临床研究；4)开发和验证替代/生物标志物来衡量疾病的分期、进展和治疗效果。